Filing Flows › Intellia Therapeutics (NTLA) › Q2 2025
Intellia Therapeutics (NTLA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Intellia Therapeutics (NTLA) reported revenue of $14.2M for the second quarter 2025 (Q2 2025), +105% from a year earlier and -14% from the quarter before. Operating margin was -772.2%, net loss $101M (710.8% of revenue).
Intellia Therapeutics, Q2 2025: revenue $14.2M (+105% year over year), operating margin -772.2%, net loss $101M, operating cash flow −$99.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.2M | -14% | +105% |
| Operating profit | −$110M | — | — |
| Net earnings | −$101M | — | — |
| Operating cash flow | −$99.6M | — | — |
What changed
Revenue was $14.2M in Q2 2025, up 105% year over year and down 14% from the previous quarter.
Operating costs exceeded revenue by $110.0M, an operating margin of -772.2%. Total costs fell 15% while revenue rose 105%. The quarter ended with a net loss of $101.3M, narrower than the previous quarter's $114.3M loss.
Operating cash flow was −$99.6M. Non-cash charges added back $2.5M of depreciation and amortization and $22.0M of share-based compensation. Working capital and other items used $22.9M. Capital expenditures of $239K exceeded it, leaving free cash flow of −$99.9M.
Questions
What was Intellia Therapeutics' revenue in the second quarter 2025?
Intellia Therapeutics (NTLA) reported revenue of $14.2M for the second quarter 2025 (Q2 2025), +105% from a year earlier and -14% from the quarter before.
Was Intellia Therapeutics profitable in the second quarter 2025?
Operating loss was $110M (-772.2% of revenue) and net loss $101M.